查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835554

抗藥性金黃色葡萄球菌治療市場（按給藥途徑、患者類型、藥物類別和分銷管道）—全球預測 2025-2032

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Administration Route, Patient Type, Drug Class, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年抗藥性金黃色葡萄球菌治療市場將成長 37 億美元，複合年成長率為 6.62%。

主要市場統計數據
基準年2024年 22.1億美元
預計2025年 23.6億美元
預測年份：2032年 37億美元
複合年成長率（%） 6.62%

全面說明現代醫療環境中影響抗藥性金黃色葡萄球菌治療的臨床、監管和衛生系統動態

抗藥性金黃色葡萄球菌因其在醫療環境中引起嚴重感染疾病的能力以及其持續適應治療壓力的能力，一直是臨床的焦點。本執行摘要提供了多方面的見解，為現代臨床管理、藥物開發和醫療系統應對措施提供參考。它強調了不斷發展的病原體生物學、不斷變化的醫療服務模式以及日益加強的監管監督如何共同影響製藥、醫院和公共衛生相關人員的優先事項。

引言部分圍繞著治療效果、安全性權衡以及急性住院和門診病人醫療服務的營運現況組裝討論。報告強調了協作管理、快速診斷途徑和一體化供應鏈韌性的必要性，同時也探討了抗生素創新與藥物開發經濟學之間的相互作用。透過這樣的背景，報告鼓勵讀者不僅了解臨床需求，還了解決定新舊治療方法的採用、指南整合和實用化的系統性槓桿。

快速診斷、新型抗生素、不斷發展的監管管道和管理的整合如何重塑抗藥性金黃色葡萄球菌的治療方法

由於分子診斷技術、新型抗生素和適應性管理政策的進步，抗藥性金黃色葡萄球菌的治療方法正在經歷重大變化。快速的即時診斷和近患者診斷技術能夠實現更早的標靶治療，減少經驗性廣效頻譜的暴露，進而影響藥物配方模式和下游抗藥性動態。同時，新型藥物和改良藥物的成熟也使可用方案更加多樣化，使臨床醫生能夠在複雜的患者群體中平衡療效和安全性。

同時，法律規範正在不斷發展，以加快獲取高需求抗生素的步伐，同時保持嚴格的安全標準，醫療衛生系統也擴大將抗生素管理納入臨床路徑和品質指標。這些變化迫使支付者和醫療服務提供者重新評估處方安排、門診輸液治療途徑以及可能改變用藥模式的家庭住院模式。因此，相關人員必須調整其商業策略、臨床教育和供應物流，以滿足更細緻入微、更依賴特定環境且對診斷製劑更敏感的需求。

2025年關稅調整對美國基本抗生素療法供應鏈策略、採購實務和取得考量的累積影響

對於依賴跨境原料藥藥和成品運輸的製造商、經銷商和醫療保健系統而言，貿易政策和關稅調整已成為重要的考量。 2025年實施的關稅調整正在影響整個價值鏈的採購成本、供應鏈路徑和合約談判，迫使企業重新評估籌資策略和庫存緩衝。對於在海外生產特種抗菌藥物及其前驅物的公司而言，這些累積的貿易成本帶來了新的壓力，迫使它們最佳化生產佈局，並盡可能探索近岸外包方案。

為了應對這一變化，製造商正在重新調整供應商契約，提高到岸成本的透明度，並加快對區域產能的投資，以降低關稅波動帶來的風險。醫院和藥房正在調整採購計劃和緊急時應對計畫，在庫存週轉和緊急採購通訊協定中優先考慮關鍵抗生素，以保持醫療服務的連續性。重要的是，關稅環境更加重視總擁有成本而非僅僅關注單位成本，鼓勵製造商和大型醫療保健採購商之間採用合作合約模式，以分散風險並確保可靠地獲得基本治療。

針對給藥途徑、病患環境、藥物類別和分銷管道的詳細細分分析揭示了臨床定位和管道特定影響

細分分析揭示了給藥途徑、患者環境、特定藥物所屬的藥物類別以及管道結構之間的重要區別，這些區別可為臨床使用、商業策略和分銷規劃提供參考。根據給藥途徑的考慮，靜脈注射和口服製劑之間存在差異，這會影響醫院的急性護理和門診的持續護理。這種差異會影響製劑的決策、照護和藥劑師的工作流程，以及門診腸外抗生素治療方案的設計。

患者類型細分對比了住院和門診病人人群，突出了治療目標的差異：急性期快速挽救生命的干涉與門診環境中的治療依從性、監測和安全考慮。藥物類別細分包括頭孢菌素類、醣肽、脂肽類、Oxazolidinone和四環素類，進一步確定了關鍵藥物，例如醣肽類中的頭孢洛林、糖肽類中的替考Teicoplanin和萬古黴素、脂肽類中的Daptomycin、Oxazolidinone類中的Linezolid和泰地唑，以及四環黴素唑烷酮類中的細胞週期蛋白和泰地細胞週期蛋白。這些類別和四環黴素水平的差異揭示了臨床定位、抗藥性特徵、不利事件監測需求以及標籤擴展和生命週期管理的潛在機會。

我們對分銷管道的細分區分了醫​​院、線上和零售藥局管道，並重點介紹了通路選擇如何影響低溫運輸物流、配藥管理、報銷機制和患者獲取模式。這些細分數據相結合，提供了一個矩陣，用於將臨床適應症映射到商業性管道，並協調不同醫療機構的教育、報銷和供應策略。

影響美洲、歐洲、中東、非洲和亞太地區治療採用、監管途徑、採購模式和供應彈性的區域動態

區域動態持續以獨特但相互關聯的方式影響臨床應用、監管預期和供應連續性。在美洲，醫療系統正強調快速採用符合管理規範的方案、投資門診輸液服務，以及由付款人主導的配方管理，這種管理更傾向於那些已證明具有明確安全性和營運效益的治療方法。此外，該地區的監管格局和報銷管道推動著嚴格的上市後和真實世界證據，附加檔和指南的納入。

歐洲、中東和非洲的管理體制和採購模式各異，有些市場採用集中競標，有些市場則採用分散採購。該地區的相關人員必須應對各種核准流程、新藥取得途徑的差異，以及在基礎設施各異的國家之間分配專用抗生素的複雜性。在抗菌素抗藥性監測和管理舉措方面開展區域合作，對於協調臨床實踐和支持跨境公共衛生應對措施正變得越來越重要。

亞太地區正經歷著治療需求的激增、醫療基礎設施的快速現代化以及門診治療的擴張。在該地區運作的市場參與企業面臨著不斷變化的法規環境，都市區正在加速採用診斷主導的複合治療方案，而農村地區則繼續依賴現有的治療方法。在不斷成長的需求和加強藥品自給自足的政策推動下，擴大區域製造能力和實現供應鏈多元化是關鍵主題。

主要企業如何平衡生命週期管理、新產品開發、供應鏈彈性和打入市場策略以應對抗藥性金黃色葡萄球菌

每家公司的策略都反映了在維護核心產品系列與追求差異化創新以應對抗藥性感染疾病、安全問題和門診病人用藥需求之間的平衡。領先的藥物開發商會分配資源來最佳化現有藥物的生命週期，同時投資於下一代化學型、替代製劑以及針對難治性感染疾病和併發症患者群體的臨床計畫。這些投資通常伴隨著策略夥伴關係和許可，以縮短開發週期並擴大地域覆蓋範圍。

企業正在探索本地製造夥伴關係，以提高供應鏈透明度，確保關鍵投入品的多種採購管道，並降低貿易中斷對區域的影響。在市場准入方面，企業專注於收集健康經濟證據，參與管理項目，並將價值溝通與付款人的優先事項結合。策略差異化也體現在臨床醫生和藥劑師的教育計畫、用於門診治療依從性的數位化支援工具，以及旨在增強臨床醫生信心和支持指南考慮的上市後合作。

為製造商、付款人和醫療保健提供者提供可行的策略建議，以協調診斷、管理、製造和證據生成，以實現治療復原力

產業領導者應優先將診斷主導的治療途徑、管理協調和供應鏈冗餘納入其策略規劃，以保障治療可近性和臨床療效。與診斷供應商和醫療保健系統建立更緊密的合作，可以促進合適的製劑研發，並減少不必要的廣譜頻譜使用。與付款人和醫院系統建立夥伴關係，還可以協調有效安全治療的獎勵，降低下游成本和不良反應。同時，實現生產來源多元化並考慮區域生產基地，可以減少貿易和關稅中斷帶來的風險，並保持關鍵藥物供應的連續性。

在研發方面，應盡可能專注於耐受性、口服生物有效性以及支持門診給藥的劑型，以擴大臨床效用，並使其更容易融入替代醫療機構。企業還應投資實用的真實世界證據項目，以證明其在常規實踐中的價值，並促進靈活的報銷管道。最後，積極參與管理計畫、監管機構和臨床協會，有助於促進指南的採納，並確保新療法和現有療法的部署方式能夠最大限度地造福患者，同時最大限度地減少抗藥性。

一種透明的多源資訊來源調查方法，結合了臨床文獻綜合、相關人員訪談、供應鏈評估和真實世界證據三角測量

本報告背後的調查方法結合了同行評審的臨床文獻、監管文件、公共衛生監測資料庫以及對臨床醫生、藥劑師、付款人和行業高管的結構化訪談。證據綜合優先考慮高品質的實驗室數據、安全報告和指南說明，以確保臨床準確性，同時，來自第一線相關人員的定性見解為關於採用、物流和患者管理的實際考慮提供了參考。在適當的情況下，我們評估了真實世界證據，以便將實驗室結果與日常實踐聯繫起來。

分析方法包括對不同給藥途徑和患者環境的治療定位進行橫斷面評估、藥物水平臨床概況圖譜繪製，以及專注於分銷、配藥和報銷機制的管道分析。透過情境分析和相關人員諮詢，評估了供應鏈和政策影響，以了解營運部門對關稅和採購變化的應對措施。在整個調查方法中，我們強調了資訊來源的透明度、對獨立輸入資料進行三角測量的結果，以及清晰地記錄驅動解釋和結論的假設。

最後，我們討論瞭如何將治療方法創新、綜合管理和營運彈性結合起來，以維持對抗藥性金黃色葡萄球菌的臨床有效性。

總而言之，抗藥性金黃色葡萄球菌的治療格局正在被診斷技術、標靶治療、適應性監管格局以及醫療服務模式的轉變所重塑。這些因素正在創造機會，透過更精準的製劑改善患者預後，並透過更安全、更便利的製劑和更可靠的證據實現商業性差異化。然而，它們也對供應鏈敏捷性、報銷參與以及與管理計劃的整合提出了新的要求，以確保藥物的永續使用和持續的臨床有效性。

因此，製造商、醫療系統和付款人的決策者必須採取一種整體方法，將治療創新與實際部署考慮聯繫起來，包括管道策略、住院到門診病人的轉變、區域監管差異等。透過協調臨床開發、上市計劃和營運彈性，相關人員可以成功駕馭新興市場並提供滿足臨床需求的治療方法，同時降低與抗藥性和供應中斷相關的風險。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 提高臨床實驗室中用於檢測 MRSA 菌株的快速分子診斷平台的整合度
  • 抗生素管理計畫的增加正在推動醫院對針對性抗 MRSA 治療的需求
  • 新型BETA-內醯胺酶抑制劑的出現，增強了BETA-內醯胺類抗生素對MRSA感染疾病的療效
  • 針對多重抗藥性MRSA菌株的噬菌體療法和協同抗生素組合的進展
  • 區域監管部門的核准加速了下一代耐甲氧西林金黃色葡萄球菌疫苗和預防藥物的商業化
  • 加大對抗菌胜肽的研發投入，作為持續性抗甲氧西林金黃色葡萄球菌菌血症的替代治療方法
  • 將人工智慧融入藥物研發流程，以識別抗藥性可能性較低的新型抗MRSA化合物

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章抗藥性金黃色葡萄球菌治療市場（依給藥途徑）

  • 靜脈
  • 口服

第9章抗藥性金黃色葡萄球菌治療市場（依患者型態）

  • 住院病人
  • 門診病人

第 10 章抗藥性金黃色葡萄球菌治療市場（依藥物類別）

  • 頭孢菌素類
    • 頭孢洛林
  • 糖肽
    • Teicoplanin
    • 萬古黴素
  • 脂肽類
    • Daptomycin
  • Oxazolidinone
    • Linezolid
    • 泰地唑胺
  • 四環黴素
    • 埃拉瓦環素
    • 細胞週期蛋白

第11章抗藥性金黃色葡萄球菌治療市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章抗藥性金黃色葡萄球菌治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章抗藥性金黃色葡萄球菌治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章抗藥性金黃色葡萄球菌治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Innovation Pharmaceuticals Inc.
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Armata Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Basilea Pharmaceutica Ltd.
    • Bausch Health Companies Inc.
    • Cardinal Health, Inc.
    • Cumberland Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries ltd
Product Code: MRR-0363DFE0369A

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is projected to grow by USD 3.70 billion at a CAGR of 6.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.21 billion
Estimated Year [2025] USD 2.36 billion
Forecast Year [2032] USD 3.70 billion
CAGR (%) 6.62%

A comprehensive orientation to the clinical, regulatory, and health system dynamics shaping treatments for methicillin-resistant Staphylococcus aureus in modern care environments

Methicillin-resistant Staphylococcus aureus remains a focal point of clinical concern due to its capacity to cause severe infections across care settings and its persistent ability to adapt to therapeutic pressures. This executive summary introduces the multidimensional considerations that inform contemporary clinical management, drug development, and health system responses. It highlights how evolving pathogen biology, changing care delivery models, and intensified regulatory scrutiny converge to shape priorities across pharmaceutical, hospital, and public health stakeholders.

The introduction frames the conversation around therapeutic efficacy, safety trade-offs, and the operational realities of delivering care to both acute inpatients and ambulatory populations. It underscores the need for coordinated stewardship, faster diagnostic pathways, and integrated supply chain resilience, while also recognizing the interplay between antimicrobial innovation and the economics of drug development. By setting this context, the report primes readers to understand not only the clinical imperatives but also the systemic levers that will determine adoption, guideline incorporation, and the practical reach of novel and existing treatments.

How rapid diagnostics, emerging antibiotic classes, evolving regulatory pathways, and stewardship integration are reshaping therapeutic approaches to resistant Staphylococcus aureus

The therapeutic landscape for methicillin-resistant Staphylococcus aureus is undergoing transformative shifts driven by advances in molecular diagnostics, novel antibiotic classes, and adaptive stewardship policies. Rapid point-of-care and near-patient diagnostic technologies are reducing empirical broad-spectrum exposure by enabling earlier targeted therapy, which in turn influences prescribing patterns and downstream resistance dynamics. Simultaneously, the maturation of newer drug classes and reformulated agents has diversified available options, allowing clinicians to balance potency with safety profiles in complex patient populations.

Concurrently, regulatory frameworks are evolving to expedite access to high-need antimicrobials while maintaining rigorous safety standards, and health systems are increasingly embedding antimicrobial stewardship within clinical pathways and quality metrics. These combined shifts are prompting payers and providers to reassess formulary placement, outpatient intravenous therapy pathways, and hospital-at-home models that can alter utilization patterns. As a result, stakeholders must adapt commercial strategies, clinical education, and supply logistics to meet demand that is more nuanced, settings-driven, and sensitive to diagnostic-supported prescribing.

The cumulative effects of 2025 tariff adjustments on supply chain strategies, procurement practices, and access considerations for essential antimicrobial therapies in the United States

Trade policy and tariff adjustments have become meaningful considerations for manufacturers, distributors, and health systems that rely on cross-border active pharmaceutical ingredient flows and finished product shipments. Tariff changes implemented in 2025 impacted procurement costs, supply chain routing, and contractual negotiations across the value chain, prompting organizations to reassess sourcing strategies and inventory buffers. For companies manufacturing specialized antimicrobials or their precursors offshore, these cumulative trade costs have introduced additional pressure to optimize manufacturing footprints and to explore nearshoring options where feasible.

In response, manufacturers have been recalibrating supplier agreements, increasing transparency around landed costs, and accelerating investments in regional manufacturing capabilities to mitigate exposure to tariff volatility. Hospitals and pharmacies have adjusted procurement timelines and contingency plans to preserve continuity of care, prioritizing critical antimicrobials in stock rotation and emergency purchasing protocols. Importantly, the tariff environment has sharpened focus on total cost of ownership rather than unit price alone, encouraging collaborative contracting models between manufacturers and large healthcare purchasers to distribute risk and ensure reliable access to essential therapies.

Detailed segmentation analysis across administration routes, patient settings, drug class subtypes and distribution channels illuminating clinical positioning and channel-specific implications

Segmentation analysis reveals important distinctions that inform clinical use, commercial strategy, and distribution planning across administration route, patient setting, drug class taxonomy with specific agents identified, and channel architecture. Examination by administration route differentiates between intravenous and oral forms, with implications for hospital-based acute management and outpatient continuity of care; this dichotomy affects formulary decisions, nursing and pharmacy workflows, and the design of outpatient parenteral antimicrobial therapy programs.

Patient-type segmentation contrasts inpatient and outpatient populations, underscoring divergent therapeutic objectives: rapid, life-saving intervention in acute settings versus treatment adherence, monitoring, and safety considerations in ambulatory care. The drug class segmentation delineates cephalosporins, glycopeptides, lipopeptides, oxazolidinones, and tetracyclines, and further identifies key agents such as ceftaroline within cephalosporins; teicoplanin and vancomycin within glycopeptides; daptomycin within lipopeptides; linezolid and tedizolid within oxazolidinones; and eravacycline and tigecycline within tetracyclines. These class- and agent-level distinctions illuminate clinical positioning, resistance profiles, adverse event monitoring requirements, and potential opportunities for label expansion or life-cycle management.

Distribution channel segmentation differentiates hospital pharmacy, online pharmacy, and retail pharmacy pathways, highlighting how channel choice influences cold chain logistics, dispensing controls, reimbursement mechanisms, and patient access models. Taken together, these segmentation lenses provide a matrix for mapping clinical indications to commercial pathways and for tailoring educational, reimbursement, and supply strategies across diverse care environments.

Regional dynamics influencing therapeutic adoption, regulatory pathways, procurement models, and supply resilience across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape clinical adoption, regulatory expectations, and supply continuity in distinct but interrelated ways. In the Americas, health systems emphasize rapid adoption of stewardship-aligned protocols, investment in outpatient infusion services, and payer-driven formulary management that privileges therapies demonstrating clear safety and operational advantages. This region's regulatory landscape and reimbursement pathways also incentivize rigorous post-market surveillance and real-world evidence generation to support label expansion and guideline inclusion.

Europe, Middle East & Africa encompasses heterogeneous regulatory regimes and diverse procurement models, where centralized tendering in some markets contrasts with fragmented, decentralized purchasing in others. Stakeholders here must navigate varying approval timelines, differential access to novel agents, and the operational complexity of distributing specialized antimicrobials across countries with disparate infrastructure. Regional collaboration on antimicrobial resistance surveillance and stewardship initiatives is increasingly important to harmonize clinical practice and to support cross-border public health responses.

Asia-Pacific presents a mix of high-volume treatment settings, rapidly modernizing healthcare infrastructure, and expanding outpatient care delivery. Market participants operating in this region encounter variable regulatory environments and accelerating adoption of diagnostic-led prescribing in urban centers, while rural healthcare delivery continues to rely on established therapeutic regimens. Regional manufacturing capacity expansion and supply chain diversification are key themes, driven by both demand growth and policy efforts to strengthen pharmaceutical self-sufficiency.

How leading companies are balancing lifecycle management, novel development, supply chain resilience, and market access strategies to address resistant Staphylococcus aureus

Company strategies reveal a balance between preserving core product portfolios and pursuing differentiated innovations to address resistant infections, safety concerns, and outpatient administration imperatives. Leading pharmaceutical developers are allocating resources to life-cycle optimization for established agents while concurrently investing in next-generation chemotypes, alternative formulations, and clinical programs that address difficult-to-treat infections and patient populations with comorbidities. These investments are frequently accompanied by strategic partnerships and licensing arrangements aimed at accelerating development timelines and expanding geographic reach.

Commercial and manufacturing plays are equally important: firms are enhancing supply chain transparency, securing multiple sourcing pathways for critical inputs, and exploring local manufacturing partnerships to reduce regional exposure to trade disruptions. On the market access front, companies are focusing on health economic evidence generation, engagement with stewardship programs, and tailored value communication that aligns with payer priorities. Strategic differentiation also manifests through educational initiatives for clinicians and pharmacists, digital support tools for outpatient therapy adherence, and post-market surveillance collaborations that build clinician confidence and support guideline consideration.

Actionable strategic recommendations for manufacturers, payers, and providers to align diagnostics, stewardship, manufacturing, and evidence generation for therapeutic resilience

Industry leaders should prioritize integrating diagnostic-driven pathways, stewardship alignment, and supply chain redundancy into strategic planning to safeguard therapeutic access and clinical impact. Establishing closer collaboration with diagnostic vendors and health systems can accelerate appropriate prescribing and reduce unnecessary broad-spectrum use, while partnerships with payers and hospital systems can align incentives around effective, safe therapies that reduce downstream costs and adverse outcomes. Simultaneously, diversifying manufacturing sources and considering regional production hubs can mitigate exposure to trade and tariff disruptions and preserve continuity of supply for critical agents.

From a development standpoint, focusing on tolerability profiles, oral bioavailability where feasible, and formulations that support outpatient administration will expand clinical utility and ease integration into alternate care settings. Companies should also invest in pragmatic real-world evidence programs to demonstrate value in routine care and to facilitate adaptive reimbursement pathways. Finally, proactive engagement with stewardship programs, regulators, and clinical societies can help shape guideline inclusion and ensure that new and existing therapies are deployed in ways that maximize patient benefit while minimizing resistance pressure.

Transparent multi-source methodology combining clinical literature synthesis, stakeholder interviews, supply chain assessment, and real-world evidence triangulation

The research methodology underpinning this report combines a synthesis of peer-reviewed clinical literature, regulatory documentation, public health surveillance databases, and structured interviews with clinicians, pharmacists, payers, and industry executives. Evidence synthesis prioritized high-quality clinical trial data, safety reporting, and guideline statements to ensure clinical accuracy, while qualitative insights from frontline stakeholders informed practical considerations around adoption, logistics, and patient management. Where appropriate, real-world evidence sources were evaluated to contextualize trial findings in routine practice.

Analytical approaches included cross-sectional assessment of therapeutic positioning across administration route and patient setting, agent-level clinical profile mapping, and channel analysis focused on distribution, dispensing, and reimbursement mechanics. Supply chain and policy impacts were assessed through scenario analysis and stakeholder consultations to capture operational responses to tariffs and procurement shifts. Throughout, the methodology emphasized transparency of sources, triangulation of findings across independent inputs, and clear documentation of assumptions that guided interpretation and conclusions.

Concluding synthesis on how therapeutic innovation, stewardship integration, and operational resilience must converge to sustain clinical effectiveness against resistant Staphylococcus aureus

In conclusion, the landscape for methicillin-resistant Staphylococcus aureus therapies is being reshaped by concurrent advances in diagnostics, targeted therapeutics, regulatory adaptation, and changing care delivery models. These forces create opportunities for improved patient outcomes through more precise prescribing and for commercial differentiation through safer, more convenient formulations and robust evidence generation. However, they also impose new requirements for supply chain agility, reimbursement engagement, and integration with stewardship programs to ensure sustainable use and continued clinical effectiveness.

Decision-makers across manufacturers, health systems, and payers must therefore adopt a holistic approach that links therapeutic innovation to practical deployment considerations, including channel strategy, inpatient-outpatient transitions, and regional regulatory variability. By aligning clinical development, market access planning, and operational resilience, stakeholders can better navigate the evolving environment and deliver therapies that meet clinical needs while mitigating the risks associated with resistance and supply disruption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of rapid molecular diagnostic platforms to detect MRSA strains in clinical laboratories
  • 5.2. Growth in antibiotic stewardship programs driving demand for targeted anti-MRSA therapeutics in hospitals
  • 5.3. Emergence of novel beta-lactamase inhibitors enhancing efficacy of beta-lactam antibiotics against MRSA infections
  • 5.4. Advances in bacteriophage therapy and synergistic antibiotic combinations targeting multi drug resistant MRSA strains
  • 5.5. Regional regulatory approvals accelerating commercialization of next generation MRSA vaccines and prophylactic agents
  • 5.6. Rising R&D investments in antimicrobial peptides as alternative treatment modalities for persistent MRSA bacteremia
  • 5.7. Integration of artificial intelligence in drug discovery workflows to identify new anti MRSA compounds with reduced resistance potential

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Administration Route

  • 8.1. Intravenous
  • 8.2. Oral

9. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Patient Type

  • 9.1. Inpatient
  • 9.2. Outpatient

10. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class

  • 10.1. Cephalosporins
    • 10.1.1. Ceftaroline
  • 10.2. Glycopeptides
    • 10.2.1. Teicoplanin
    • 10.2.2. Vancomycin
  • 10.3. Lipopeptides
    • 10.3.1. Daptomycin
  • 10.4. Oxazolidinones
    • 10.4.1. Linezolid
    • 10.4.2. Tedizolid
  • 10.5. Tetracyclines
    • 10.5.1. Eravacycline
    • 10.5.2. Tigecycline

11. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Innovation Pharmaceuticals Inc.
    • 15.3.2. Johnson & Johnson Services, Inc.
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Armata Pharmaceuticals, Inc.
    • 15.3.5. AstraZeneca PLC
    • 15.3.6. Basilea Pharmaceutica Ltd.
    • 15.3.7. Bausch Health Companies Inc.
    • 15.3.8. Cardinal Health, Inc.
    • 15.3.9. Cumberland Pharmaceuticals Inc.
    • 15.3.10. Merck & Co., Inc.
    • 15.3.11. Novartis AG
    • 15.3.12. Paratek Pharmaceuticals, Inc.
    • 15.3.13. Pfizer Inc.
    • 15.3.14. Takeda Pharmaceutical Company Limited
    • 15.3.15. Teva Pharmaceutical Industries ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)

TABLE 253.